Abstracts tagged "Clinical practice"

Abstract Number: 1690 • 2017 ACR/ARHP Annual Meeting
Nailfold Capillary Counts Are Associated with Clinical Manifestations in Connective Tissue Disease Japanese Patitents
Atsushi Kondo¹, Tomohiro Kameda¹, Miharu Izumikawa¹, Hiromi Shimada², Shusaku Nakashima¹, Risa Wakiya¹, Mikiya Kato¹, Norimitsu Kadowaki¹ and Hiroaki Dobashi¹, ¹Internal Medicine Division of Hematology, Rheumatology, and Respiratory Medicine, Kagawa University, Kagawa, Japan, ²Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan
Background/Purpose: Connective tissue diseases (CTD) patients have various clinical manifestation including pulmonary hypertension (PH) and digital ulcer (DU). Especially, Raynaud’s phenomenon (RP) is one of…
Abstract Number: 816 • 2017 ACR/ARHP Annual Meeting
Comparison between Giacta Trial and a Multicenter Series of Giant Cell Arteritis Patients from Clinical Practice with Tocilizumab
Nuria Vegas-Revenga¹, Javier Loricera¹, Antonio Mera², Eva Pérez- Pampín², Santos Castañeda³, Lucia C. Domínguez-Casas¹, José Luis Martín-Varillas⁴, Belén Atienza-Mateo⁴, MC Gonzalez-Vela¹, Jose L. Hernández⁵, Miguel Angel González-Gay⁴ and Ricardo Blanco⁴, ¹Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Rheumatology, Complejo Hospitalario Universitario de Santiago. Galicia. Spain, Santiago de Compostela, Spain, ³Hospital Universitario de La Princesa, Madrid. Spain, Madrid, Spain, ⁴Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁵Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain
Background/Purpose: GiACTA study is a randomized, phase III controlled clinical trial of tocilizumab (TCZ) in giant cell arteritis (GCA) (1,2). Our aim was to compare…
Abstract Number: 2059 • 2017 ACR/ARHP Annual Meeting
Allopurinol Dose-Titration Patterns Relative to Serum Uric Acid Levels in Gout Patients: US Electronic Health Record Data
An-Chen Fu, Douglas C.A. Taylor and David S. Reasner, Ironwood Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Gout is the most common form of inflammatory arthritis and is caused by elevated serum uric acid (sUA). Allopurinol is a first-line urate-lowering therapy…
Abstract Number: 1046 • 2017 ACR/ARHP Annual Meeting
Biological and Targeted Synthetic Dmards’ Prior Authorization Time Is Significantly Reduced with Pharmacy Presence in the Rheumatology Clinic
Wendy Ramey¹, Kristine M. Lohr², Matt Zeltner¹, Haley Herrell Postonl¹, Andrew Johannemann¹, Aric D. Schadler¹ and Aleksander Lenert³, ¹University of Kentucky, Lexington, KY, ²Rheumatology, University of Kentucky, Lexington, KY, ³Internal Medicine, Div. of Rheumatology, University of Kentucky, Lexington, KY
Background/Purpose: Treatment with biological DMARDs (bDMARD) and targeted synthetic DMARDs (tsDMARD) has led to improved outcomes for chronic rheumatic diseases. Current treat-to-target (T2T) strategy relies…
Abstract Number: 2452 • 2017 ACR/ARHP Annual Meeting
In Real-World Clinical Practice, Patients Switching from IV to SC Abatacept Maintain Clinical Efficacy after Switch
Rieke Alten¹, HM Lorenz², X Mariette³, H Nüßlein⁴, M Galeazzi⁵, F Navarro⁶, M Chartier⁷, J Heitzmann⁸, C Rauch⁹ and M Le Bars⁷, ¹Schlosspark-Klinik University Medicine, Berlin, Germany, ²University Hospital, Heidelberg, Germany, ³Université Paris-Sud, Paris, France, ⁴University of Erlangen-Nuremberg, Nuremberg, Germany, ⁵University of Siena, Siena, Italy, ⁶Hospital Universitario Virgen Macarena, Seville, Spain, ⁷Bristol-Myers Squibb, Rueil-Malmaison, France, ⁸Excelya, Boulogne-Billancourt, France, ⁹Bristol-Myers Squibb, Munich, Germany
Background/Purpose: Patients (pts) with RA may be able to switch from IV to SC abatacept with no loss of efficacy or safety concerns, but data…
Abstract Number: 1078 • 2017 ACR/ARHP Annual Meeting
Initial Combination Therapy Versus Step-up Therapy Is More Effective and Less Costly As a Treat to Target Strategy for RA: A Markov Model Based upon the Dutch Rheumatoid Arthritis Monitoring Registry Cohorts
Celine J. van de Laar¹, Laura M.M. Steunebrink², Martijn A.H. Oude Voshaar³ and Harald E. Vonkeman⁴, ¹Transparency in Healthcare B.V., Hengelo, Netherlands, ²Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ³University of Twente, Department of Psychology, Health and Technology, Enschede, Netherlands, ⁴koningsplein, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands
Background/Purpose: Adjusting medication of patients with rheumatoid arthritis (RA) until predefined disease activity targets are met, i.e. Treat to Target (T2T), is the currently recommended…
Abstract Number: 2530 • 2017 ACR/ARHP Annual Meeting
Clinical Specialty Setting As a Determinant for Disease Management in Patients with Psoriatic Arthritis: An Interim Analysis of the Cross-Sectional Observational Study
Wolf-Henning Boehncke¹, Rudolf Horváth², Ediz Dalkiliç³, Sȏnia A L Lima⁴, Masato Okada⁵, Maja Hojnik⁶, Fabiana Ganz⁷ and Ennio Lubrano⁸, ¹Geneva University Hospital and University of Geneva, Geneva, Switzerland, ²Department of Pediatric and Adult Rheumatology, University Hospital Motol, Prague, Czech Republic, ³Department of Internal Medicine, Division of Rheumatology, Uludag University School of Medicine, Gorukle, Bursa, Turkey, ⁴ABC Medical School, Santo André, Brazil, ⁵Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ⁶AbbVie, Ljubljana, Slovenia, ⁷AbbVie AG, Baar, Switzerland, ⁸Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy
Background/Purpose: Evidence suggests that timely and effective management can improve long-term outcomes in patients (pts) with psoriatic arthritis (PsA); however factors influencing treatment management decisions…
Abstract Number: 1088 • 2017 ACR/ARHP Annual Meeting
Staff Protocol in Rheumatology Clinics Reduces Population-Level Rate of High Blood Pressure
Christie M. Bartels¹, Edmond Ramly², Emmanuel Sampene³, Diane Lauver⁴, Patrick McBride⁵ and Heather Johnson⁵, ¹Rheumatology/Medicine, University of Wisconsin - Madison, Madison, WI, ²Industrial and Systems Engineering, University of Wisconsin College of Engineering, Madison, WI, ³Biostatistics, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴University of Wisconsin-Madison School of Nursing, Madison, WI, ⁵Cardiology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: The Centers for Disease Control and Prevention director has said “nothing will save more lives” than protocols to control blood pressure (BP). BP is…
Abstract Number: 2532 • 2017 ACR/ARHP Annual Meeting
The Relationship between the Degree of Skin Involvement and Joint Activity in Patients with Psa: Experience from the Corrona Registry
Philip J Mease¹, Carol J. Etzel², Jeffrey Lisse³, April W Armstrong⁴, William J Huster³, Sabrina Rebello², Rhiannon Dodge², Talia M Muram³, Sarah Al Sawah³, Mwangi J Murage³, Jeffrey D Greenberg² and William Malatestinic³, ¹Department of Rheumatology, Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Keck School of Medicine, University of Southern California, Los Angeles, CA
Background/Purpose: Prior studies have shown an inconsistent relationship between skin and joint symptoms in patients with comorbid PsO and PsA1-3. The objective of the…
Abstract Number: 1118 • 2017 ACR/ARHP Annual Meeting
Diabetes and Gout: Real-World Evidence Evaluating Patient Characteristics, Treatment Patterns, and Health Care Utilization
Douglas C.A. Taylor¹, An-Chen Fu¹ and Robert Morlock², ¹Ironwood Pharmaceuticals, Inc., Cambridge, MA, ²YourCareChoice, Ann Arbor, MI
Background/Purpose: Gout and type 2 diabetes mellitus (T2DM) are common in the United States (US), but little is known about potential associations of T2DM and…
Abstract Number: 2533 • 2017 ACR/ARHP Annual Meeting
Current Psa Therapy Impacts the Relationship between the Degree of Skin Invlovment and Joint Activity
Philip J Mease¹, Carol J. Etzel², Jeffrey Lisse³, April W Armstrong⁴, William J Huster³, Sabrina Rebello², Rhiannon Dodge², Talia M Muram³, Sarah Al Sawah³, Mwangi J Murage³, Jeffrey D Greenberg² and William Malatestinic³, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Keck School of Medicine, University of Southern California, Los Angeles, CA
Background/Purpose: Simultaneous control of joint symptoms and degree of skin involvement has been linked to improvement in health-related quality of life in patients with coexistent…
Abstract Number: 1233 • 2017 ACR/ARHP Annual Meeting
Establishing and Maintaining a Volunteer Charity Rheumatology Clinic: One Clinic’s Experience
Narender Annapureddy¹, Michelle J. Ormseth², Julie Barnes³ and James Gore⁴, ¹Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ²Rheumatology, Vanderbilt Medical Center, Nashville, TN, ³Vanderbilt University Medical Center, Nashville, TN, ⁴Vanderbilt Rheumatology Cool Springs, Franklin, TN
Establishing and Maintaining a Volunteer Charity Rheumatology Clinic: One Clinic’s Experience Background/Purpose: In 2015, about 16% of adults under age 65 in Tennessee were uninsured.…
Abstract Number: 1382 • 2017 ACR/ARHP Annual Meeting
Characteristics of Patients with Rheumatoid Arthritis and Atlanto-Axial Pannus
Jessica Williams¹, Andrew Joyce², Glenn Gaviola¹, Zacharia Isaac^1,2 and Joerg Ermann³, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA, ³Harvard Medical School, Boston, MA
Background/Purpose: Formation of pannus, an inflammatory tissue mass, in the atlanto-axial joint of the cervical spine is an important sequela of rheumatoid arthritis (RA). Atlanto-axial…
Abstract Number: 1443 • 2017 ACR/ARHP Annual Meeting
Adverse Drug Reactions Due to Disease Modifying Drugs in a Cohort of Patients with Incident Rheumatoid Arthritis
Zulema Rosales Rosado^1,2, Dalifer Freites Núñez², Cristina Lajas Petisco¹, Esperanza Pato Cour¹, Leticia Leon², Judit Font Urgelles¹, Juan A Jover Jover¹ and Lydia A Alcazar², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Background/Purpose: There is a well-known risk of developing adverse drug reactions (ADR) in rheumatology due, mainly, to the Disease Modifying Drugs (DMARD) used. After more…
Abstract Number: 1460 • 2017 ACR/ARHP Annual Meeting
Predictive Factors Associated with Successful Down-Titration of Biologics for Rheumatoid Arthritis Patients in Clinical Practice
Takaaki Komiya¹, Kaoru Minegishi-Takase², Natsuki Sakurai¹, Yuichiro Sato¹, Hideto Nagai³, Naoki Hamada³, Yumiko Sugiyama³, Naomi Tsuchida¹, Yutaro Soejima³, Yosuke Kunishita³, Hiroto Nakano³, Daiga Kishimoto³, Koji Kobayashi², Reikou Kamiyama³, Ryusuke Yoshimi³, Yukiko Asami³, Yohei Kirino³, Shigeru Ohno⁴ and Hideaki Nakajima³, ¹Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, ³Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁴Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan
Background/Purpose: Randomized clinical trials have shown that if a patient is in sustained remission, biological disease-modifying anti rheumatic drugs (bDMARDs) therapy can be tapered in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.